Lipocine Inc LPCN 深 滬
已收盤 02-06 16:00:00 美东时间
8.49
+0.770
+9.97%
華盛通- 最 高8.91
- 今 開7.84
- 成交量 12.07万股
- 最 低 7.84
- 昨 收 7.72
- 總市值 4713.59万
- 52周最高 12.37
- 市盈率 靜 --
- 換手率 2.17%
- 52周最低 2.52
- 委 比 84.84%
- 總股本 555.19万
- 歷史最高 340.00
- 量 比 1.61
- 振 幅 13.86%
- 歷史最低 2.52
- 每 手 1
- 風險率 1.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 奈飞绩后遭13家大行下调目标价；齐昂银行、美国合众银行获多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从9美元升至50美元；韦德布什：维持Ardelyx, Inc."跑赢大市"评级，目标价从16美元升至19美元
01-22 15:09
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX Jan 21 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including IBM, KLA and WEX, on Wednesday. HIGHLIGHTS * IBM IBM.N : JP Morgan raises target price to $312 from $290 * KLA Corp KLAC.O : Deut
01-21 16:26
Lipocine Completes Enrollment, Patient Dosing In Its Phase 3 Clinical Study Of LPCN 1154 To Treat Postpartum Depression
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that enrollment and participant dosing
01-20 21:10
Lipocine Nears Full Enrollment In Phase 3 PPD Trial, Topline Results Expected Q2 2026
Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline results on track for the second quarter of 2026SALT LAKE CITY, Dec. 16, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a
2025-12-16 21:10
Lipocine Showcases LPCN 2101 at Epilepsy Meeting
An update from Lipocine ( ($LPCN) ) is now available. Lipocine presented poster...
2025-12-12 06:28
Lipocine Updates Corporate Presentation for Investors
Lipocine ( ($LPCN) ) just unveiled an update. Lipocine has updated its corporat...
2025-11-18 22:58
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
2025-11-14 10:43
HC Wainwright & Co. Maintains Buy on Lipocine, Lowers Price Target to $7
HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and lowers the price target from $8 to $7.
2025-11-13 20:55
Lipocine Q3 EPS $(0.59) Misses $(0.55) Estimate, Sales $114.574K Miss $238.000K Estimate
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.55) by 8.26 percent. This is a 34.09 percent decrease over losses of $(0.44) per share from the
2025-11-06 21:28
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
SALT LAKE CITY, Nov. 4, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effe...
2025-11-04 21:00
